Form 8-K - Current report:
SEC Accession No. 0001193125-25-124500
Filing Date
2025-05-22
Accepted
2025-05-22 06:23:27
Documents
18
Period of Report
2025-05-20
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d927226d8k.htm   iXBRL 8-K 34489
2 EX-4.1 d927226dex41.htm EX-4.1 76268
3 EX-4.2 d927226dex42.htm EX-4.2 76769
4 EX-5.1 d927226dex51.htm EX-5.1 13684
5 EX-10.1 d927226dex101.htm EX-10.1 206087
6 EX-99.1 d927226dex991.htm EX-99.1 10554
10 GRAPHIC g927226reed.jpg GRAPHIC 5653
  Complete submission text file 0001193125-25-124500.txt   657996

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA jagx-20250520.xsd EX-101.SCH 2877
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE jagx-20250520_lab.xml EX-101.LAB 17994
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE jagx-20250520_pre.xml EX-101.PRE 11279
20 EXTRACTED XBRL INSTANCE DOCUMENT d927226d8k_htm.xml XML 3636
Mailing Address 200 PINE STREET SUITE 400 SAN FRANCISCO CA 94104
Business Address 200 PINE STREET SUITE 400 SAN FRANCISCO CA 94104 415-371-8300
Jaguar Health, Inc. (Filer) CIK: 0001585608 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36714 | Film No.: 25974686
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)